Dose-Dense Therapy in Aggressive Lymphoma

Arbeitsgemeinschaft medikamentoese Tumortherapie

Status

Conditions: Lymphoma

Treatments: Drug: CEOP/IMVP-Dexa chemotherapy

Study type: Expanded Access

Funder types: Other

Identifiers

NCT00517894

NHL-5

Details and patient eligibility

About

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Full description

Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 and 70 years of age
• Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified
• Measurable disease
• All stages

Exclusion criteria

• Lymphoblastic or Burkitt histology
• CNS-disease
• HIV-positive
• pregnant or lactating women
• Pretreatment
• Other malignancy
• Concomitant diseases that forbid chemotherapy